A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb

被引：0
|
作者：
Joy, Stephen T. [1 ]
Henley, Matthew J. [1 ,2 ]
De Salle, Samantha N. [1 ,2 ]
Beyersdorf, Matthew S. [1 ,2 ]
Vock, Isaac W. [1 ,3 ]
Huldin, Allison J. L. [1 ,4 ]
Mapp, Anna K. [1 ,2 ,4 ]
机构：
[1] Joy, Stephen T.
[2] 1,Henley, Matthew J.
[3] 1,De Salle, Samantha N.
[4] 1,Beyersdorf, Matthew S.
[5] 1,Vock, Isaac W.
[6] 1,Huldin, Allison J. L.
[7] 1,2,Mapp, Anna K.
来源：
Mapp, Anna K. (amapp@umich.edu) | 1600年 / American Chemical Society卷 / 143期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Journal article (JA)
引用
收藏
页码：15056 / 15062
相关论文
共 50 条
  • [41] Targeting oncogenic enhancer activity with a small-molecule CBP/P300 bromodomain inhibitor
    Raisner, Ryan
    Bainer, Russell
    Chan, Emily
    Garcia, Jesse
    Merchant, Mark
    Gascoigne, Karen
    CANCER RESEARCH, 2018, 78 (13)
  • [42] Probing p300/CBP Associated Factor (PCAF)-Dependent Pathways with a Small Molecule Inhibitor
    Modak, Rahul
    Basha, Jeelan
    Bharathy, Narendra
    Maity, Koustav
    Mizar, Pushpak
    Bhat, Akshay V.
    Vasudevan, Madavan
    Rao, Vinay Kumar
    Kok, Wai Kay
    Natesh, Nagashayana
    Taneja, Reshma
    Kundu, Tapas K.
    ACS CHEMICAL BIOLOGY, 2013, 8 (06) : 1311 - 1323
  • [43] Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors
    Yang, Yaxi
    Zhang, Rukang
    Li, Zhaojun
    Mei, Lianghe
    Wan, Shili
    Ding, Hong
    Chen, Zhifeng
    Xing, Jing
    Feng, Huijin
    Han, Jie
    Jiang, Hualiang
    Zheng, Mingyue
    Luo, Cheng
    Zhou, Bing
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (03) : 1337 - 1360
  • [44] Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases
    Michaelides, Michael R.
    Kluge, Arthur
    Patane, Michael
    Van Drie, John H.
    Wang, Ce
    Hansen, T. Matthew
    Risi, Roberto M.
    Mantei, Robert
    Hertel, Carmen
    Karukurichi, Kannan
    Nesterov, Alexandre
    McElligott, David
    de Vries, Peter
    Langston, J. William
    Cole, Philip A.
    Marmorstein, Ronen
    Liu, Hong
    Lasko, Loren
    Bromberg, Kenneth D.
    Lai, Albert
    Kesicki, Edward A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (01): : 28 - 33
  • [45] CBP/p300 is a cell type-specific modulator of CLOCK/BMAL1-mediated transcription
    Hiroshi Hosoda
    Kenichi kato
    Hidenori Asano
    Motonori Ito
    Haruno Kato
    Taku Iwamoto
    Akinobu Suzuki
    Shoichi Masushige
    Satoshi Kida
    Molecular Brain, 2
  • [46] Mutations in Multiple Domains of c-Myb Disrupt Interaction with CBP/p300 and Abrogate Myeloid Transforming Ability
    Pattabiraman, Diwakar R.
    Sun, Jane
    Dowhan, Dennis H.
    Ishii, Shunsuke
    Gonda, Thomas J.
    MOLECULAR CANCER RESEARCH, 2009, 7 (09) : 1477 - 1486
  • [47] Tax recruitment of CBP/p300, via the KIX domain, reveals a potent requirement for acetyltransferase activity that is chromatin dependent and histone tail independent
    Georges, SA
    Giebler, HA
    Cole, PA
    Luger, K
    Laybourn, PJ
    Nyborg, JK
    MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (10) : 3392 - 3404
  • [48] Fragment Screening and Druggability Assessment for the CBP/p300 KIX Domain through Protein-Observed 19F NMR Spectroscopy
    Gee, Clifford T.
    Koleski, Edward J.
    Pomerantz, William C. K.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2015, 54 (12) : 3735 - 3739
  • [49] CBP/p300 is a cell type-specific modulator of CLOCK/BMAL1-mediated transcription
    Hosoda, Hiroshi
    Kato, Kenichi
    Asano, Hidenori
    Ito, Motonori
    Kato, Haruno
    Iwamoto, Taku
    Suzuki, Akinobu
    Masushige, Shoichi
    Kida, Satoshi
    MOLECULAR BRAIN, 2009, 2
  • [50] Oncogenic human papillomavirus hijacks p300 to drive viral transcription, creating a therapeutic vulnerability that can be exploited with selective p300/CBP catalytic inhibitors
    Kobylarz, M.
    Larke, M.
    Glore, W.
    Shum, M.
    Mori, K.
    Cohen, E.
    Pandey, A.
    Hopkins, T.
    McKeown, M.
    Obholzer, N.
    Trotter, B.
    Carvajal, L.
    Rahl, P.
    Lin, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S95 - S95
12345